Navigation Links
Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting

nt; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, VALSTAR(R) and SUPPRELIN(R)-LA; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, DELATESTRYL and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations and other risks. Indevus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Indevus Reports Positive Data From Phase III NEBIDO Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:10/30/2014)... , October 30, 2014 ... probiótico LGG contribuye a adquirir tolerancia a la ... alergia a la proteína de la leche de la ... primera infancia. Hasta ahora, la APLV se trataba ... se ha demostrado que es posible adquirir tolerancia ...
(Date:10/30/2014)... 2014  TWi Pharmaceuticals, Inc. today announced that it ... and Drug Administration (FDA) on its Abbreviated New Drug ... the generic equivalent to Eisai Inc.,s Aricept® 23mg.  Aricept® ... TWi Pharmaceuticals is preparing to launch the product ... Pharmaceuticals USA , at the earliest ...
(Date:10/30/2014)... 29, 2014 Electrodes are devices that ... be amplified to diagnose as well as treat ... medical devices facilitate the detection of chemical reactions ... and neurons of the patients. In addition, few ... alternating current to perform minimally invasive surgical procedures. ...
Breaking Medicine Technology:Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager focused ... people save money through its innovative discount card program. ... in the new health care system, the Paramount Rx ... relationship between consumers, businesses and the pharmacy industry. ... today with medical costs is the rising price of ...
(Date:10/30/2014)... Home Care Assistance – Halton/Peel Region ... in-home senior care, is weighing in on a recent ... The study, performed by the University of Illinois, analyzed ... over a week-long period and observed how much time ... By examining the structural soundness of the white matter ...
(Date:10/30/2014)... 30, 2014 REV'D Provision Co. announced ... available through a unique service called, The Feed ... empower the everyday athlete. The Feed has taken the ... created a system to pass that information on to ... is now available on The Feed!” says REV’D® marketing ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- When it comes to heart ... men to delay care when they have symptoms that spell ... to the hospital with a more severe or advanced stage ... study author Catherine Kreatsoulas, a Fulbright Scholar and research fellow ... news release from the Heart and Stroke Foundation of Canada. ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Eating a low-carb, ... to treat, according to new research. A ... modified Atkins diet, that focuses on foods like bacon, ... help reduce seizures in adults whose condition doesn,t improve ... 35 percent of people with epilepsy whose seizures are ...
Breaking Medicine News(10 mins):Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... PFCD Executive Director Ken Thorpe and Alan Aviles, ... York City Health and Hospitals Corporation, spoke to ... information technology (HIT) in the economic stimulus package. ... make the immediate investments necessary to ensure America,s ...
... for Children,s First Annual Awards CeremonyWASHINGTON, Jan. 14 ... Senators Richard Lugar (R-IN), Christopher Dodd (D-CT), Barbara ... Betty McCollum (D-MN-04) with the first annual GAC ... recognizes those who have done outstanding work on ...
... New research published in the January issue of the ... laparoscopic removal of gastrointestinal stromal tumors (GISTs) is safe and ... after an average follow-up time of three and a-half years. ... from special cells in the wall of the gastrointestinal tract ...
... who allegedly was seriously injured by Medtronic, Inc.,s Infuse(R) ... by Medtronic has sued the company, according to James ... LLC.The firms, along with co-counsel Lieff, Cabraser, Heimann & ... on behalf of Paul and Susan Antonelli, of Amsterdam, ...
... Jan. 14 Environmental Tectonics Corporation ... announced financial results for the third quarter and the first ... 2008. Thirteen weeks ended November 28, 2008 compared to thirteen ... a net loss of $113,000, or $0.04 per share (basic ...
... ARBOR, Mich. By the time they have been ... so impaired that they cannot give informed consent to ... left with the decision, but there is no clear ... research about the increasingly common disease is often stalled. ...
Cached Medicine News:Health News:PFCD Experts Cite Health Information Technology as Key Investment for Economic Stimulus 2Health News:Senators Lugar, Dodd, Boxer and Representatives Lee and McCollum Receive GAC Children's Champion Award 2Health News:Study shows surgery provides good long-term outcomes for patients with gastrointestinal cancers 2Health News:Medtronic, Inc. and Medtronic Sofamor Danek USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC 2Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 2Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 3Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 4Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 5Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 6Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 7Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 8Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 9Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 10Health News:Most support Alzheimer's research based on family consent 2Health News:Most support Alzheimer's research based on family consent 3
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: